儿童移植受者更昔洛韦/缬更昔洛韦剂量个体化的贝叶斯估测器与有限采样策略的充分验证
本研究在儿童实体器官或干细胞移植受者中,基于回顾性数据用迭代两阶段贝叶斯法建立并验证了有限采样策略的贝叶斯估测器,用于估算更昔洛韦0-24小时AUC。开发集中1h/2h/3h和1h/3h策略对更昔洛韦的RMSE分别为9.1%和12.3%,1h/2h/6h和1h/6h策略对缬更昔洛韦的RMSE分别为13.3%和11.8%;独立验证集中VGCV和GCV分别有7例(13%)和5例(14%)暴露分类错误。
要点
- 更昔洛韦用1h/2h/3h三采血点,缬更昔洛韦用1h/2h/6h三采血点可准确估算AUC0-24。
- 验证集中VGCV和GCV分别有13%和14%的儿童暴露分类错误。
- 该策略支持药代动力学增强的治疗药物监测用于儿童移植受者。
核心结论
- 基于有限采样策略的贝叶斯估测器可准确估算儿童移植受者更昔洛韦AUC0-24,支持药代动力学增强的治疗药物监测。
研究设计与样本
- 回顾性纳入接受更昔洛韦或缬更昔洛韦且按标准诊疗有更昔洛韦浓度可用的实体器官或干细胞移植受者,用迭代两阶段贝叶斯法进行药代动力学建模并开发贝叶斯估测器。
- 验证数据集包括额外的儿童实体器官或干细胞移植受者,以及既往研究中入组的儿童肾或肝移植受者。
- 评估三采血点或两采血点的多种组合,依据开发集和三个独立验证集中的相对平均偏倚、标准差和均方根误差。
主要发现
- 开发集中更昔洛韦1h/2h/3h策略的平均偏倚/标准差/均方根误差为-1.4%/9.3%/9.1%,1h/3h策略为-3.5%/12.2%/12.3%。
- 开发集中缬更昔洛韦1h/2h/6h策略的平均偏倚/标准差/均方根误差为0.7%/13.5%/13.3%,1h/6h策略为-0.1%/12.1%/11.8%。
- 独立验证集中,使用这些贝叶斯估测器和有限采样策略,缬更昔洛韦和更昔洛韦分别有7例(13%)和5例(14%)儿童暴露被错误分类。
关键数值与推荐
- 更昔洛韦推荐采血点为给药后1h/2h/3h,缬更昔洛韦推荐采血点为给药后1h/2h/6h,各采集三份血浆样本。
- 更昔洛韦1h/2h/3h策略开发集均方根误差9.1%,缬更昔洛韦1h/2h/6h策略开发集均方根误差13.3%。
- 独立验证集中缬更昔洛韦暴露分类错误7例(13%),更昔洛韦暴露分类错误5例(14%)。
临床怎么用
- 儿童移植受者使用更昔洛韦或缬更昔洛韦时,可按给药后1h/2h/3h(GCV)或1h/2h/6h(VGCV)采集三份血浆,用经验证的贝叶斯估测器估算AUC0-24以个体化剂量。
- 该有限采样策略适用于药代动力学增强的治疗药物监测,但需注意独立验证集中仍存在一定比例的暴露分类错误。
局限性
- 本研究为回顾性设计,建模和验证数据来自特定儿童移植人群,外推至其他人群需谨慎。
- 独立验证集中缬更昔洛韦和更昔洛韦分别有13%和14%的儿童暴露被错误分类,提示估测器存在一定误判风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Given a high pharmacokinetic inter-individual variability and a low exposure target achievement, ganciclovir (GCV) therapeutic drug monitoring is sometimes used in children. We aimed to develop and validate Bayesian estimators based on limited sampling strategies for the estimation of GCV area under the concentration-time curve from 0 to 24 h in pediatric transplant recipients treated with valganciclovir (VGCV) or GCV. METHODS: Solid organ transplant or stem-cell transplant recipients who received GCV or VGCV and had available GCV concentrations per standard of care were retrospectively included in this study for pharmacokinetic modeling and development of Bayesian estimators using the iterative two-stage Bayesian method. Validation datasets included additional child recipients of a solid organ transplant or stem-cell transplant, and child recipients of a kidney or liver transplant enrolled in a previous study. Various combinations of three or two sampling times, applicable in clinical practice, were assessed based on the relative mean bias, standard deviation, and the root mean square error in a development dataset and three independent validation datasets. RESULTS: In the development dataset, the mean bias/standard deviation/root mean square error for the 1 h/2 h/3 h and 1 h/3 h limited sampling strategies were - 1.4%/9.3%/9.1% and - 3.5%/12.2%/12.3%, respectively for GCV, while for VGCV, the mean bias/standard deviation/root mean square error for the 1 h/2 h/6 h and 1 h/6 h limited sampling strategies were 0.7%/13.5%/13.3% and - 0.1%/12.1%/11.8%, respectively. In the independent validation datasets, seven (13%) and five (14%) children would have had misclassifications of their exposure using these Bayesian estimators and limited sampling strategies for VGCV and GCV, respectively. CONCLUSIONS: Three plasma samples collected at 1 h/2 h/3 h and 1 h/2 h/6 h post-dose for GCV and VGCV respectively, are sufficient to accurately determine GCV area under the concentration-time curve from 0 to 24 h for pharmacokinetic-enhanced therapeutic drug monitoring.
引用
- Franck B, Autmizguine J, Åsberg A, et al. Thoroughly Validated Bayesian Estimator and Limited Sampling Strategy for Dose Individualization of Ganciclovir and Valganciclovir in Pediatric Transplant Recipients. Clin Pharmacokinet. 2021. PMID: 34050910. doi:10.1007/s40262-021-01034-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。